References

  1. Stedman's Medical Dictionary. Baltimore: Williams & Wilkins. 26th edition, 1995.
  2. Arnaud MJ. The pharmacology of caffeine. Prog Drug Res. 1987:31;273-313.
  3. Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev. 1993;45(1):43-85.
  4. Bonati M, Latini R, Tognoni G. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. Drug Metab Rev. 1985;15:1355-1383.
  5. Kalow W. Variability of caffeine metabolism in humans. Drug Res. 1985;35:319-324.
  6. Yoovathaworn KC, Sriwatanakul K, Thithapandah A. Influence of caffeine on aspirin pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1986;11:71-76.
  7. Price VF, Gale GR. Effects of caffeine on biotransformation and elimination kinetics of acetaminophen in mice. Res Commun Chem Pathol Pharmacol. 1987;57:249-260.
  8. Bottini PB, Devane JG, Kelly JG, et al. The effect of caffeine on ibuprofen pharmacokinetics. Acta Pharmacol Toxicol. 1986;59:54.
  9. Robayo JR. Vascular headache. In Kathcher BS, Young LY, Koda-Kimble MA, eds. Applied Therapeutics, ed 3. Spokane: Applied Therapeutics Inc, 1983; pp 1103, 1105-1107.
  10. Rail TW, Schleifer LS. Oxytocin, prostaglandins, ergot alkaloids, and other drugs; tocolytic agents. In Gilman AG, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basis of Therapeutics, ed 7. New York: Macmillan, 1985; pp 937-939.
  11. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: naproxen sodium vs. ergotamine plus caffeine. Headache. 1988;28:263-266.
  12. Bruce M, Lader M, Marks V, et al. The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects. Br J Clin Pharmacol. 1986;22:81-87.
  13. Clubley M, Bye CE, Henson TA, et al. Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects, and EEG activity. Br J Clin Pharmacol. 1979;7:157-163.
  14. File SA, Bond AJ, Lister RF. Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol. 1982;2:102-106.
  15. Lieberman HR, Wurtman RJ, Emde GG, et al. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmcol. 1987;7:315-320.
  16. Lieberman HR, Wurtman RJ, Emde AA, et al. The effects of low dose caffeine on human performance and mood. Psychopharmcology. 1987;92:308-312.
  17. Goldstein J. Caffeine in headache therapy. Presented at the Dannemiller Memorial Educational Foundation Conference, "The Practicing Physician's Approach to the Difficult Headache Patient," 23-27 July 1999.
  18. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther. 1978;24:40-45.
  19. May DC, Jarboe CH, van Bakel, et al. Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther. 1982;31:656-661.
  20. Patwardhan RV, Desmond PV, Jonson RF, et al. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med. 1980;95:603-608.
  21. Desmond PV, Patwardhan RV, Parker R, et al. Effect of cimetidine and other antihistamines on the elimination of antipyrine, phenacetin, and caffeine. Life Sci. 1980;26:1261-1268.
  22. Beach CA, Mays DC, Guiler RC, et al. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986;39:265-270.
  23. Mitchell MC, Hoyumpa AM, Schenker S, et al. Inhibition of caffeine elimination by short-term ethanol administration. J Lab Clin Med. 1983;101:826-834.
  24. Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2005;105(1):110-113.
  25. Gilbert RM, Marshman JA, Schweider M, et al. Caffeine content of beverages as consumed. Can Med Assoc J. 1976;114:205-207.
  26. Regan C. To your health. Restaurants USA. 1987;11:36-37
  27. Temple JL. Caffeine use in children: what we know, what we have left to learn, and why we should worry. Neurosci Biobehav Rev. 2009;33(6):793-806.
  28. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46(9):1334-1343.
  29. Bigal M. Migraine chronification--concept and risk factors. Discov Med. 2009;8(42):145-150.
  30. Caffeine content for coffee, tea, soda and more. Available at: http://www.mayoclinic.com/health/caffeine/AN01211.
  31. Cafergot. Available at: http://www.drugs.com/mtm/cafergot-oral-rectal.html.
  32. Esgic. Available at: http://www.drugs.com/pro/esgic-plus.html.
  33. Fiorinal. Available at: http://www.drugs.com/pro/fiorinal.html.
  34. Fioricet. Available at: http://www.drugs.com/pro/fioricet.html
  35. Bode AM, Dong Z. The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett. 2007;247(1):26-39.
  36. Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment Pharmacol Ther. 2007;26(1):1-8.
  37. Geleijnse JM. Habitual coffee consumption and blood pressure: an epidemiological perspective. Vasc Health Risk Manag. 2008;4(5):963-970.
  38. Knutti R, Kurihara S. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol. 1987;21:121-126.
  39. Parsons WD, Pelletier JG. Delayed elimination of caffeine by women in the last 2 weeks of pregnancy. Can Med Assoc J. 1982;127:377-380.
  40. Joesoef MR, Beral V, Rolfs T, et al. Are caffeinated beverages risk factors for delayed conception? The Lancet. 1990;335:136-137.
  41. Laska EM, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA. 1984;251:1711-1718.
  42. Wallenstein S. Analgesic studies of aspirin in cancer patients. Proceedings of the Aspirin Symposium. 1975;5-10.
  43. Booy RH. Pijnbestrijding met eenvoudige analgetica in de tandheelkunde. Ned Tijdschr Tandheelkd. 1972;79:69-75.
  44. Migliardi JR, Armellino JJ, Friedman M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther. 1994;56:576-586.
  45. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating headache pain of an acute migraine attack. Arch Neurology. 1998;55:210-217.
  46. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005;45:973-982.
  47. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006;46:444-453.
  48. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2005;25:776-787.
  49. Sandrini G, Cerbo R, Del Bene E, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract. 2007;61(8):1256-1269.
  50. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160.
  51. Silberstein SD, Oleson J, Bousser ME, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia. 2005;25:460-465.
  52. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3(8):475-483.
  53. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology. 2003;61(2):160-164.
  54. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46(5):766-772.
  55. Gallagher RM. The role of the primary care provider in the appropriate use of analgesics for headache. Headache Q. 1997;Suppl:22-28.
  56. Dalessio DJ. On the safety of caffeine as an analgesic adjuvant. Headache Q. 1994;5:125-127.
  57. Mathew NT. Chronic refractory headache. Neurology 1993;43:826-833.
  58. O'Brien CP. Is there an abuse potential for caffeine-containing analgesic combinations? In, ed. Holtz A. Advances in the management of acute pain. International Congress and Symposium Series No. 218:11-15.
  59. Rahman A, Segasothy M, Samad SA, et al. Analgesic use and chronic renal disease in patients with headache. Headache 1993;33:442-445.
  60. Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321-328.
  61. Limmroth V, Kazaeawa Z, Fritsche G, et al. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet. 1999;353:378.
  62. Kaube H, May A, Pfaffenrath V, et al. Sumatriptan misuse in daily chronic headache. BMJ. 1994;308:1573.
  63. Gaist D, Tsirpoulus I, Sindrup SH, et al. Inappropriate use of sumatriptan: population-based register and interview study. BMJ. 1998;316:1352-1353.
  64. Fritsche G, Diener HC. Medication overuse headaches - what is new? Expert Opin Drug Saf. 2002;1(4):331-338.
  65. Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs. 2005;19(6):483-497.
  66. Saper JR. Diagnosis and symptomatic treatment of migraine. Headache . 1997;37(suppl 1):S1-S14.
  67. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Available at: http://www.psych.org/MainMenu/Research/DSMIV/DSMIVTR.aspx.
  68. Greden JF, Victor BS, Fontaine P, et al. Caffeine-withdrawal headache: a clinical profile. Psychosomatics. 1980;21(5):411-418.
  69. Dreisbach RH, Pfeiffer C. Caffeine Withdrawal headache. J Lab Clin Med. 1943;28:1212-1218.
  70. Dews PB, Curtis GL, Hanford KJ, et al. The frequency of Caffeine Withdrawal in a population-based survey and in a controlled, blinded, pilot experiment. J Clin Pharmacol. 1999;39:1221-1232.
  71. Juliano LM, Griffths RR. A critical review of Caffeine Withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl). 2004:176;1-29.
  72. Griffiths RR, Woodson PR. Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther. 1988;246:21-29.
  73. Couturier EG, Hering R, Steiner TJ. Weekend attacks in migraine patients: caused by Caffeine Withdrawal? Cephalalgia. 1992;12:99-100.
  74. Satel S. Is caffeine addictive?--a review of the literature. Am J Drug Alcohol Abuse. 2006;32(4):493-502.

Support for this program was provided by unrestricted educational grants from Bristol-Myers Squibb (2000) and Novartis Consumer Health (2010).